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Abstract
Background: Dietary supplements targeting fat loss and increased thermogenesis are prevalent within the sport
nutrition/weight loss market. While some isolated ingredients have been reported to be efficacious when used at
high dosages, in particular in animal models and/or via intravenous delivery, little objective evidence is available
pertaining to the efficacy of a finished product taken by human subjects in oral form. Moreover, many ingredients
function as stimulants, leading to increased hemodynamic responses. The purpose of this investigation was to
determine the effects of a finished dietary supplement on plasma catecholamine concentration, markers of
lipolysis, metabolic rate, and hemodynamics.
Methods: Ten resistance trained men (age = 27 ± 4 yrs; BMI = 25 ± 3 kg· m-2; body fat = 9 ± 3%; mean ± SD)
ingested a dietary supplement (Meltdown®, Vital Pharmaceuticals) or a placebo, in a random order, double blind
cross-over design, with one week separating conditions. Fasting blood samples were collected before, and at 30,
60, and 90 minutes post ingestion and were assayed for epinephrine (EPI), norepinephrine (NE), glycerol, and free
fatty acids (FFA). Area under the curve (AUC) was calculated for all variables. Gas samples were collected from
30–60 minutes post ingestion for measurement of metabolic rate. Heart rate and blood pressure were recorded
at all blood collection times.
Results: AUC was greater for the dietary supplement compared to the placebo for NE (1332 ± 128 pg·mL-1·90
min-1 vs. 1003 ± 133 pg·mL-1·90 min-1; p = 0.03), glycerol (44 ± 3 μg·mL-1·90 min-1 vs. 26 ± 2 μg·mL-1·90 min-1; p
< 0.0001), and FFA (1.24 ± 0.17 mmol·L-1·90 min-1 vs. 0.88 ± 0.12 mmol·L-1·90 min-1; p = 0.0003). No difference
between conditions was noted for EPI AUC (p > 0.05). For all variables, values were highest at 90 minutes post
ingestion. Total kilocalorie expenditure during the 30 minute collection period was 29.6% greater (p = 0.02) for
the dietary supplement (35 ± 3 kcal) compared to placebo (27 ± 2 kcal). A condition main effect was noted for
systolic blood pressure (p = 0.04), with values increasing from 117 ± 2 mmHg to 123 ± 2 mmHg with the dietary
supplement, while remaining unchanged for placebo. No other hemodynamic changes were noted (p > 0.05).
Conclusion: The dietary supplement results in an acute increase in plasma NE and markers of lipolysis, as well
as metabolic rate. This occurs without altering hemodynamic variables in a clinically significant manner.
Intervention studies to determine the impact of this dietary supplement on weight/fat loss are warranted.
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Background
The prevalence of obesity has grown to epidemic propor-
tions within the United States in recent years, with an esti-
mated 400 million people now being classified as obese
[1]. Methods to treat this growing problem traditionally
include increased physical activity and modification of
dietary intake, as well as surgical, pharmaceutical, and
nutritional supplement interventions [2]. Due to the dif-
ficulty of maintaining regular physical activity and opti-
mal dietary practices, many individuals seek weight
management support in either a pharmaceutical or dietary
supplement. Furthermore, due to concern over potential
adverse outcomes associated with prescription drug use,
many consumers prefer over the counter (OTC) dietary
supplements. While some isolated OTC ingredients have
been reported to be efficacious in terms of increasing
lipolysis, most have only been studied at high dosages,
often using animal models or in vitro systems, as opposed
to human subjects and oral intake [3]. Despite this fact,
many dietary supplement manufacturers use such ingredi-
ents in their formulations and make claims based on sci-
entific findings that may have little or no relevance to the
actual product of sale. This is particularly concerning
when the dosage of the "key ingredient" used in many fin-
ished products is often far lower than that used in the orig-
inal research studies. Moreover, many ingredients (e.g.,
ephedrine) function as stimulants, leading to an unde-
sired and potentially harmful increase in heart rate and
blood pressure.
One ingredient that appears to have promise as a dietary
aid is yohimbine. Yohimbine is a member of the yohim-
bane  family, a large group of indole alkaloids derived
from botanical sources. Pharmacologically, yohimbine is
well-characterized as an alpha-2-adrenergic receptor
antagonist and has been demonstrated to increase lipoly-
sis in vitro [3], possibly due to its ability to stimulate a reli-
able increase in blood norepinephrine (NE); a finding
evident in multiple studies involving human subjects
receiving single dosages [4-7]. While not as universal a
finding, other work has also demonstrated a significant
increase in blood epinephrine (EPI) levels with yohim-
bine intake [7,8]. The increase in NE with acute yohim-
bine ingestion has been associated with an increase in
blood free fatty acid levels [4,5,8], indicating a lipolytic
effect of this nutrient. This is likely mediated by the inter-
action of NE with hormone sensitive lipase (HSL), the rate
limiting enzyme in lipolysis [9]. Yohimbine may also aid
in lipolysis by acting to improve blood flow [10], and
hence, the transport of fatty acids to peripheral tissues to
undergo oxidation.
Synephrine (also known as Bitter Orange, Sour Orange,
and Seville Orange) has been suggested as an effective die-
tary aid, as this trace endogenous bioamine activates beta-
3 receptors and may result in lipolysis and appetite sup-
pression [11]. Since April 12, 2004 when the Food and
Drug Administration banned the sale of dietary supple-
ments containing ephedrine alkaloids, interest in syne-
phrine has risen sharply. In fact, many ephedrine-free
products currently being sold contain synephrine as an
active ingredient.
Caffeine is a central nervous system stimulant, technically
classified as a methylxanthine, which has a temporary
effect on increasing lipolysis and thermogenesis [12,13].
This is likely due to its action on the "second messenger
system" known as 3', 5'-cyclic adenosine monophosphate
(cAMP), which is a crucial component in fatty acid metab-
olism where it functions to activate cAMP dependent pro-
tein kinase [14]. Caffeine has the ability to both decrease
the breakdown of cAMP, as well as increase cAMP produc-
tion via beta-adrenergic receptor independent and
dependent mechanisms, respectively [12]. Caffeine is also
an adenosine antagonist, capable of blocking the inhibi-
tory effects of adenosine on further NE release, ultimately
resulting in an increased or sustained level of NE in the
circulation [15]. As such, caffeine is popular as a dietary
weight/fat loss aid.
It is unknown what the potential effects of the above com-
bination of ingredients would be on blood catecho-
lamines and markers of lipolysis. Recently, these
ingredients (in addition to other ingredients as presented
in Figure 1) have been combined for delivery as one con-
venient capsule (Meltdown®; Vital Pharmaceuticals, Inc.).
Two initial studies using this product have noted an
increase in subjects' resting [16,17] and post exercise [17]
metabolic rate when compared to placebo. However, nei-
ther of these studies included blood measurement of cat-
echolamines or markers of lipolysis. Therefore, the
interpretation of findings is limited. It was our purpose in
the proposed research to extend these findings by study-
ing the impact of this dietary supplement on blood cate-
cholamine levels, markers of lipolysis, metabolic rate, and
hemodynamics in human subjects. Using a double blind,
randomized, crossover design, we hypothesized that the
dietary supplement would result in an increase in NE,
markers of lipolysis, and metabolic rate in our sample of
resistance trained men, in comparison to a placebo.
Methods
Subjects
Ten healthy, resistance trained men participated in this
investigation. Subjects completed a medical history and
physical activity questionnaire to determine eligibility.
No subject was a smoker or had diagnosed metabolic or
cardiovascular disease. Subjects were considered to be
well-trained and performed resistance exercise for 4.6 ±
2.2 hrs per week for 8.4 ± 6.6 yrs. Descriptive characteris-Journal of the International Society of Sports Nutrition 2009, 6:4 http://www.jissn.com/content/6/1/4
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tics are provided in Table 1. Subjects were instructed not
to deviate from their current training regimen during the
course of the study with the exception of refraining from
exercise for the 48 hours prior to each testing day. All
experimental procedures were performed in accordance
with the Helsinki Declaration. The University of Memphis
Human Subjects Committee approved all experimental
procedures. All subjects provided both verbal and written
consent prior to participating in this study.
Conditions and Testing
The dietary supplement used in this investigation (Melt-
down®, Vital Pharmaceuticals, Inc., Davie, FL) included
yohimbine, caffeine, and synephrine as the primary active
ingredients. Please see Figure 1 for a description of the die-
tary supplement. All capsules used in this investigation
were from the same bottle and produced in accordance
with Good Manufacturing Practices (GMPs). Prior to pro-
duction, all raw materials were tested for ingredient
potency and the finished product was verified for label
claims. Subjects consumed three capsules of the dietary
supplement or an identical looking placebo (corn starch,
microcrystalline cellulose, super refined sesame oil, pro-
pylene glycol fatty acid ester, safflower oil, sunflower oil)
in a double blind, cross-over design. No food was allowed
until testing was completed, although water was allowed
ad libitum and matched for both days of testing (mean
intake = 500 mL).
Subjects reported to the laboratory in a fasted state (> 8
hours), without caffeine consumption during the past 8
hours. All testing was done between 0600–1000 hours.
Following a 10 minute quiet rest period, a baseline blood
sample was obtained (0 min). Subjects then ingested
either the supplement or placebo, in the presence of an
investigator. Subjects remained inactive during the entire
90 minute test period. At 30 minutes post ingestion, a sec-
ond blood sample was taken (30 min). A measurement of
resting metabolic rate, using indirect calorimetry, was
then started and continued for 30 minutes. Subjects were
positioned in a seated posture and gas analysis was per-
formed with breath-by-breath collection using a Sensor-
Medics Vmax 229 metabolic system (Yorba Linda, CA)
and facemask. Subjects were familiarized to the facemask
prior to the collection period, instructed to simply breathe
normally, and to remain quiet and awake during the 30
minute measurement period. Subjects were allowed to
read during the collection period. All gas collection took
place in a temperature and humidity controlled labora-
tory, and both the flow sensor and gas analyzers were cal-
ibrated prior to data collection. Total oxygen
consumption (L·min-1) was determined and total kilocal-
orie expenditure was estimated from this value. Respira-
tory exchange ratio was also determined from gas
collection (CO2/O2), and used as a crude measure of sub-
strate utilization. At the end of the 30 min collection
period, a third blood sample was taken (60 min). A final
blood sample was taken at 90 min (90 min). Measure-
ments of heart rate (via heart rate monitor) and blood
pressure (via auscultation) were taken immediately prior
to each blood sample, in a seated position. Procedures
were identical for both test sessions (supplement and pla-
cebo).
Label description of Meltdown® Figure 1
Label description of Meltdown®.
Table 1: Descriptive characteristics of 10 exercise trained men.
Variable Value
Age (yrs) 27 ± 4
Height (cm) 175 ± 7
Weight (kg) 77 ± 11
Body mass index (kg·m-2)2 5  ±  3
Body fat (%)* 9 ± 3
Years Resistance Exercise 8 ± 7
Hours/wk Resistance Exercise 5 ± 2
Data are mean ± SD.
* Determined from 7-site skinfold analysis use Lange calipers and Siri 
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Blood Processing and Biochemistry
A total of four venous blood samples (7 mL per draw)
were taken from subjects' forearm via needle and Vacu-
tainer® by a trained phlebotomist. Following collection,
blood samples were immediately processed in a refriger-
ated centrifuge in order to obtain plasma (4°C for 15 min
at 2000 × g). Plasma samples were stored in multiple aliq-
uots at -80°C. All assays were performed within two
months of sample collection, in duplicate, and on first
thaw. NE and EPI were determined using an enzyme
linked immunosorbent assay (2-CAT ELISA, BA 10–1500;
Rocky Mountain Diagnostics) following the instructions
of the manufacturer (Labor Diagnostika Nord GmbH &
Co. KG). In this competitive ELISA, NE and EPI are
extracted by using a cis-diol-specific affinity gel, acylated,
and then derivitized enzymatically. The coefficient of var-
iation (CV) for NE and EPI was 9.8% and 6.9%, respec-
tively. Glycerol was determined using the Free Glycerol
Determination Kit (FG0100) and Glycerol Standard
(G7793), following the instructions of the manufacturer
(Sigma Aldrich). The CV for glycerol was 7.8%. Free fatty
acids were determined using the Free Fatty Acid Quantifi-
cation Kit (K612-100) following the instructions of the
manufacturer (BioVision). The CV for FFA was 9.2%.
Diet and Physical Activity
During the 24 hours before each test day, subjects con-
sumed prepackaged meal replacement drinks and bars
provided by the project sponsor. These contained a mix of
protein, carbohydrate, and fat. Subjects were given 3
shakes and 3 bars and instructed to consume as many as
they desired, with no other food or calorie containing
drinks. The amount consumed during the day preceding
the initial test day was mimicked during the day preceding
the second test day. The average intake of subjects was a
combination of 5 shakes/bars. This provided approxi-
mately 2000 kilocalories. Regarding physical activity, sub-
jects were asked to avoid strenuous exercise during the 48
hours preceding the test days.
Statistical Analysis
Area under the curve (AUC) was calculated for each bio-
chemical variable for both conditions using the trapezoi-
dal method (AUCG) as described in detail by Pruessner et
al. [18]. Statistical comparisons for biochemical (AUCG)
and metabolic data were made between conditions using
t-tests. Biochemical data, in addition to heart rate and
blood pressure data, were also compared using a 2 (con-
dition) × 4 (time) analysis of variance (ANOVA). Tukey's
post hoc tests were used where appropriate. All analyses
were performed using JMP statistical software (version
4.0.3, SAS Institute, Cary, NC). Statistical significance was
set at P ≤ 0.05. The data are presented as mean ± SEM,
except for subject descriptive characteristics (mean ± SD).
Results
All subjects successfully completed all aspects of the study.
AUC was greater for the dietary supplement compared to
the placebo for NE (Figure 2B; p = 0.03), glycerol (Figure
3A; p < 0.0001), and FFA (Figure 3B; p = 0.0003). No dif-
ference was noted between conditions for EPI (Figure 2A;
p > 0.05). For all variables, values were highest at 90 min-
utes post ingestion. When performing the 2 × 4 ANOVA
for biochemical variables, a condition main effect was
noted for NE (p < 0.0001), with no time effect (p = 0.13)
or interaction noted (p = 0.25). A condition main effect
was noted for EPI (p = 0.04), with no time effect (p = 0.09)
or interaction noted (p = 0.36). An interaction was noted
for glycerol (p = 0.0006), with values higher for supple-
ment compared to placebo at 30, 60, and 90 minutes post
ingestion (p < 0.05), and higher for supplement at all
times post ingestion compared to pre ingestion (p < 0.05).
A condition main effect was noted for FFA (p = 0.0003),
with no time effect (p = 0.08) or interaction noted (p =
0.32). Total kilocalorie expenditure during the 30 minute
collection period was 29.6% greater (p = 0.02) for the die-
tary supplement compared to placebo (Figure 4A). No dif-
ference was noted between conditions for respiratory
exchange ratio (Figure 4B; p > 0.05). A condition main
effect was noted for systolic blood pressure (p = 0.04),
with values increasing from 117 ± 2 mmHg to 123 ± 2
mmHg with the dietary supplement, while remaining
unchanged for placebo. No other hemodynamic changes
were noted (p > 0.05). Hemodynamic data are presented
in Table 2.
Discussion
Data from the present investigation indicate that the die-
tary supplement Meltdown®, ingested at the exact dosage
as recommended by the manufacturer, results in an acute
increase in plasma NE, glycerol and FFA (when measured
using AUC; in addition to a condition main effect for EPI
when measured using ANOVA), as well as an increase in
metabolic rate. This occurs despite only a mild increase in
heart rate and systolic blood pressure, with no increase in
diastolic blood pressure. Although metabolic rate was
higher for Meltdown® compared to placebo, it should be
noted that the typical day-to-day variance in this measure
is estimated at 4–6% [19]. Hence, this should be consid-
ered when interpreting our findings.
Although it is impossible to determine which of the active
ingredients contained with this and other finished prod-
ucts are actually responsible for the observed effects, it is
likely that the present findings are due to the three pri-
mary ingredients in Meltdown®; yohimbine, caffeine, and
synephrine. Based on our findings of minimal hemody-
namic changes, coupled with the significant increase in
NE, we believe that yohimbine may be the most impor-
tant component to this supplement.Journal of the International Society of Sports Nutrition 2009, 6:4 http://www.jissn.com/content/6/1/4
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Plasma epinephrine (A) and norepinephrine (B) data for 10 men consuming Meltdown® and placebo in a randomized cross-over  design Figure 2
Plasma epinephrine (A) and norepinephrine (B) data for 10 men consuming Meltdown® and placebo in a rand-
omized cross-over design. Data are mean ± SEM. * Greater norepinephrine AUC for Meltdown® compared to placebo (p = 
0.03).
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Plasma glycerol (A) and free fatty acid (B) data for 10 men consuming Meltdown® and placebo in a randomized cross-over  design Figure 3
Plasma glycerol (A) and free fatty acid (B) data for 10 men consuming Meltdown® and placebo in a randomized 
cross-over design. Data are mean ± SEM. * Greater glycerol (p < 0.0001) and FFA (p = 0.0003) AUC for Meltdown® com-
pared to placebo.
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The process of fatty acid oxidation involves the complex
interplay between HSL, the specific hormones acting to
stimulate HSL, and the receptors that bind to these hor-
mones in order for them to exert their effect [9]. Although
many hormones may be involved in fatty acid metabo-
lism (e.g., growth hormone, thyroid hormone, ACTH,
cortisol), the catecholamines EPI and NE appear para-
mount [9]. These interact with both beta adrenergic recep-
tors (EPI and NE), as well as alpha-adrenergic receptors
(NE). Depending on which receptors are activated, lipoly-
sis can be either stimulated (beta) or inhibited (alpha),
with optimal HSL activity observed in the presence of low
insulin levels.
While yohimbine itself has been reported in several stud-
ies to increase blood NE [4-7], NE is not selective in its
binding. That is, while it can bind beta receptors (1, 2, and
3 sub-class), it also binds alpha receptors (1 and 2 sub-
class) [20]. Therefore, in a way, NE may both "stimulate"
and "inhibit" fatty acid mobilization. Specifically, activa-
tion of alpha 2 receptors inhibits further release of NE,
allowing NE to act as its own negative feedback signal.
Because yohimbine is a selective alpha-2-adrenergic
receptor antagonist, it can function to impair the negative
feedback loop specific to NE. This effect, coupled with the
stimulatory effect of yohimbine on NE release, allows for
a net increase in circulating NE. This was clearly demon-
strated in the present investigation (Figure 2B). This
occurred despite the relatively low dosage of yohimbine
provided (9 mg) compared to other studies using dosages
equal to 2–5 times this amount [4-7]. It is possible that
the form of yohimbine used in the dietary supplement
could be responsible for the significant increase in NE, as
a combination of yohimbine HCl, alpha-yohimbine, and
11-hydroxy yohimbine make up the total yohimbine
complex provided in Meltdown®.
Total kilocalories (A) and mean respiratory exchange ratio  (B) data for 10 men consuming Meltdown® and placebo in a  randomized cross-over design Figure 4
Total kilocalories (A) and mean respiratory 
exchange ratio (B) data for 10 men consuming Melt-
down® and placebo in a randomized cross-over 
design. Data are mean ± SEM. * Greater total kilocalories 
for Meltdown® compared to placebo (p = 0.02).
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Table 2: Hemodynamic data for 10 men consuming Meltdown® and placebo in a randomized cross-over design.
Variable 0 min 30 min 60 min 90 min
Heart rate (bpm)
Meltdown®
59 ± 3 63 ± 2 62 ± 2 63 ± 2
Heart rate (bpm)
Placebo
59 ± 3 60 ± 3 62 ± 3 60 ± 3
Systolic Blood Pressure (mmHg)
Meltdown® *
1 1 7  ±  21 2 2  ±  31 2 3  ±  21 2 2  ±  3
Systolic Blood Pressure (mmHg)
Placebo
1 1 8  ±  21 1 8  ±  21 1 7  ±  11 1 6  ±  1
Diastolic Blood Pressure (mmHg)
Meltdown®
72 ± 1 71 ± 2 72 ± 2 70 ± 2
Diastolic Blood Pressure (mmHg)
Placebo
72 ± 1 72 ± 2 71 ± 1 71 ± 1
Data are mean ± SEM.
*Condition effect; higher systolic blood pressure for Meltdown® compared to placebo (p = 0.04).
No other statistically significant effects noted (p > 0.05).Journal of the International Society of Sports Nutrition 2009, 6:4 http://www.jissn.com/content/6/1/4
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Although HSL may be ultimately stimulated by the
increase in EPI and NE, it is the initial binding of the cat-
echolamines to beta receptors that begins the secondary
intracellular activation of adenylyl cyclase [21]. Activation
of adenylyl cyclase results in an increased production of
cAMP [14], which in turn leads to the activation of a cAMP
dependent protein kinase (PKA) [22]. It is PKA that ulti-
mately activates HSL leading to triglyceride breakdown
and subsequent release of glycerol and FFA into the circu-
lation.
Caffeine possesses lipolytic/thermogenic effects due to its
ability to both decrease the breakdown of cAMP as well as
increase cAMP production via beta-adrenergic receptor
independent and dependent mechanisms, respectively
[12]. The independent effects are due to caffeine's ability
to directly inhibit cAMP degradation, by inhibiting the
cyclic nucleotide phosphodiesterase [23] and blocking
adenosine receptors (anti-lipolytic agent receptors). The
direct effect results from an increase in catecholamine
release following caffeine ingestion, which may be sec-
ondary to the previously described adenosine inhibition
[12]. The potential role of synephrine as a lipolytic agent
is also specific to its ability to interact with beta receptors
(3 sub-class), thereby promoting lipolysis via the above
described cAMP dependent mechanism [24].
In addition to yohimbine, caffeine, and synephrine, sev-
eral other ingredients are included within Meltdown®.
These include the amphetamine-like/thyroid stimulating
agent phenylethylamine (PEA), which has been reported
to cause a significant reduction in 24 hour food intake,
and a dose dependent reduction in body weight gain in
rats [25]. This may be due partly to the effect of PEA on
stimulating blood catecholamine levels and inhibiting
their reuptake [26]. The monoamine oxidase inhibitor
methyl hordidine is also contained within this supple-
ment. Hordinine is structurally similar to EPI and has
been shown to liberate NE from its storage site, in addi-
tion to inhibiting NE metabolism [27]. The lipolytic agent
methyl tetradecylthioacetic acid is also included. It is
known to stimulate beta oxidation [28] and is clearly
involved in lipid transport and utilization [29]. Finally,
the satiety hormone cholecystokinin (CCK-8) may have
an influence on food intake if provided over a prolonged
period of time.
Collectively, the above ingredients appear to represent a
substantial list of potentially effective lipolytic agents.
While it is possible that these additional ingredients may
have contributed to the overall effectiveness of the dietary
supplement in regards to our findings of increased lipoly-
sis and metabolic rate, based on the relatively low dosages
provided (in comparison to those used in prior investiga-
tions where these ingredients have been studied in isola-
tion), it is difficult to state with certainty that their
contribution was significant.
It is important to note that our findings for all blood var-
iables following intake of the dietary supplement were
highest at the 90 minute post ingestion mark. It is indeed
possible that further increases may have been observed at
times distant to this. Further study to determine the time
course of increased lipolysis is warranted. Based on the
work of Hoffman et al. [16] who noted an increase in met-
abolic rate during hours one, two, and three following
ingestion of this dietary supplement, it is likely that the
corresponding blood variables would also remain ele-
vated during this time. If so, the potential for increased fat
mobilization is apparent. More importantly, if coupled
with acute bouts of exercise, fat "burning" may be
increased significantly during this period of time, poten-
tially resulting in decreased body weight/body fat. Of
course, longer term intervention studies are needed to test
this hypothesis.
Conclusion
In conclusion, we report that the finished product Melt-
down®, ingested at the exact dosage as recommended by
the manufacturer, results in an acute increase in plasma
NE, glycerol, and FFA (measured using AUC), EPI (meas-
ured using ANOVA), as well as metabolic rate. This occurs
despite a minimal increase in heart rate and systolic blood
pressure. Our findings are specific to a sample of young,
healthy, and lean resistance trained men. Further study is
needed to determine if similar or more pronounced find-
ings are observed in a sample of overweight/sedentary
men and women, who often respond to a greater extent to
such treatment. Longer term studies are also needed to
determine if the lipolytic effects of this supplement extend
beyond 90 minutes post ingestion. Finally, intervention
studies are warranted to determine the impact of this die-
tary supplement on weight/fat loss.
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